On July 11, during the 2026 Atrial Fibrillation Academic Symposium (CAFS 2026), MicroPort EverPace hosted a lunch symposium titled "Smart Dual-Energy · Perfusion-Guided." The session focused on the latest R&D achievements, academic progress, and clinical applications of domestically produced electrophysiology mapping and ablation devices.

The symposium was co-chaired by Professor Chen Minglong from Jiangsu Provincial People's Hospital, Professor Chen Qi from the Second Affiliated Hospital of Nanchang University, and Professor Yi Fu from Xijing Hospital, Air Force Medical University. Several domestic electrophysiology experts engaged in discussions centered around the technical differentiation of pulsed field ablation (PFA) and the clinical application strategies of dual-energy pressure-monitoring ablation catheters.

At the "Smart Dual-Energy · Perfusion-Guided" lunch symposium, Professor Xia Yunlong from the First Affiliated Hospital of Dalian Medical University delivered opening remarks. Professor Xia reviewed the nearly 30-year development history of the AF Symposium since its inception in 1997, noting that it has become an important platform for high-level academic exchange and the continuation of clinical friendships. Regarding the symposium's theme of "dual-energy and pressure-monitoring innovative technologies," Professor Xia pointed out that with the growing clinical adoption of PFA, how to achieve efficient switching and energy stacking between RF and PFA during procedures—enhancing efficiency while ensuring clinical safety—has become a key concern for electrophysiologists. He expressed that this symposium aims to provide strategic references for clinicians and wished the event great success.

During the congress, MicroPort EverPace held a joint launch ceremony for the PulseMagic™ TrueForce™ Pulsed Field Ablation Catheter (hereinafter referred to as the "PulseMagic™ TrueForce™ Pressure-Monitoring PFA Catheter") and the EasyEcho™ Ultrasound catheter (hereinafter referred to as the "EasyEcho™ ICE Catheter").

Professor Chen Minglong from Jiangsu Provincial People's Hospital, Professor Chen Qi from the Second Affiliated Hospital of Nanchang University, Professor Chu Huimin from the First Affiliated Hospital of Ningbo University, Professor Wu Gang from Shanghai General Hospital, Professor Wang Zulu from the General Hospital of Northern Theater Command, Professor Yi Fu from Xijing Hospital, Air Force Medical University, and Dr. Sun Yiyong, President of MicroPort EverPace, jointly attended the ceremony.

With all eyes on the stage, the experts collectively pressed the launch button, officially announcing the joint market introduction of the PulseMagic™ TrueForce™ Pressure-Monitoring PFA Catheter and the EasyEcho™ ICE Catheter.

Professor Wang Zulu from the General Hospital of Northern Theater Command highlighted the technical features and clinical application data of the PulseMagic Spiral Pulsed Field Ablation Catheter (hereinafter referred to as the "PulseMagic™ Spiral Magnetic-Electrical Positioning PFA Catheter") developed by MicroPort EverPace's strategic partner Shangyang Medical, focusing on its use in pulmonary vein isolation.

Clinical Considerations in Catheter Design:

Professor Wang Zulu noted that current PFA systems differ in electrode arrangement, materials, configuration, and energy delivery modes. Clinical catheter selection should match the patient's pulmonary vein antrum diameter. The average pulmonary vein diameter in China is close to 20 mm, so large-diameter loop catheters are recommended as the first choice, while smaller catheters (<18 mm) may struggle to achieve single-shot isolation in certain anatomies.

Broadband Ablation:

The PulseMagic™ Spiral catheter features a spiral three-dimensional double-loop structure that forms a "tower" configuration upon entering the pulmonary vein. This design simultaneously covers the antrum and the ostium, achieving both internal and external tissue contact, effectively widening the ablation zone and improving continuity, reducing the risk of residual gaps, and enhancing the integrity of single-shot electrical isolation. The catheter leverages the Columbus™ 3D EP Navigation System, combined with impedance feedback, for real‑time monitoring of tissue contact and ablation effect.

Safety and Exploratory Use:

PFA has a certain degree of myocardial tissue selectivity. Clinical data show that post‑procedural unconjugated bilirubin elevation is not significant, confirming good blood compatibility. Beyond standard pulmonary vein isolation, the catheter has been used in 5%–7% of clinical study cases for posterior wall BOX ablation and superior vena cava isolation. Professor Wang Zulu cautioned that coronary artery spasm risk should be considered during posterior wall ablation, with nitroglycerin prepared in advance.

Mapping-Ablation Integration:

A single catheter combines modeling, mapping, and ablation functions, reducing the need for device exchanges during the procedure. With this integrated design, catheter costs per procedure are correspondingly reduced.

Expert Discussion:

Professor Tian Kejun from the First Affiliated Hospital of Gannan Medical University shared his center's experience with PFA, noting that the device's overall energy delivery modes meet clinical needs. The expert panel noted that the catheter supports not only overall discharge but also segmented and multi-loop flexible configurations. For special sites such as the cavotricuspid isthmus, precise positioning is required due to the larger coverage area, and beginners should exercise caution. Professor Yu Fengyuan from Fuwai Hospital, Chinese Academy of Medical Sciences, pointed out that the international promotion of PFA technology requires close attention to overseas registration compliance, next‑generation real‑time contact assessment capabilities, and differentiated reimbursement pathways.

Professor Chu Huimin from the First Affiliated Hospital of Ningbo University introduced the technical characteristics of a magnetic‑positioning pressure‑irrigation integrated catheter equipped with both pulsed field and RF dual‑energy capabilities.

Deep and Complex Anatomical Ablation:

Traditional bipolar ablation may result in insufficient lesion depth—leading to post‑procedural recurrence—when addressing hypertrophic or special anatomical sites such as the left ventricular papillary muscles, mid‑septal ventricular myocardium, epicardium, or accessory pathways, due to large electrode spacing and limited penetration. The unipolar mode of MicroPort EverPace's dual‑energy catheter offers strong penetration, enabling continuous and transmural deep lesions.

Animal Studies and Clinical Case Feedback:

Animal studies have shown that the catheter achieves substantial lesion depths in papillary muscle and epicardial regions, with maximum depths reaching 14.3 mm. In pulse mode (10g contact force), a single discharge achieves a 3 mm lesion depth, and 5 discharges reach 6 mm; ablation of ventricular papillary muscles takes approximately 5.5 seconds. In clinical applications, the catheter has been used to manage multiple complex non‑outflow tract premature beats and accessory pathway cases.

Dual‑Energy Usage Strategies:

Professor Chu Huimin introduced that physicians can select appropriate dual‑energy strategies based on real‑time intracardiac electrogram changes during the procedure, synergistically enhancing lesion depth and width. Given that PFA offers myocardial targeting advantages—with high selectivity for fibrotic myocardium, strong visualization, and immediate effect—occasional transient ST‑segment elevation or coronary spasm has been observed in experiments, but overall safety metrics are superior to traditional energy modalities.

Expert Discussion:

Professor Li Jun from the Second Affiliated Hospital of Air Force Medical University discussed methods for verifying irreversible electroporation and strategies for achieving transmural lesions in thick myocardium. Professor Chu Huimin noted that ablation efficacy can be assessed through cardiac magnetic resonance (CMR) follow‑up and isoproterenol/sotalol pharmacological challenge. Professor Li Houwei from the Second Affiliated Hospital of Harbin Medical University noted that unipolar mode can achieve continuous deep lesions, but when ablating special regions such as the para‑Hisian area or left bundle branch region, attention should be paid to voltage and number of discharges to avoid irreversible conduction block. If transient third‑degree AV block occurs during the procedure, observation for 5 to 10 minutes is recommended to assess conduction recovery.

Professor Wu Gang from Shanghai General Hospital presented the application progress and technical characteristics of the pressure‑sensing dual‑energy catheter in AF ablation.

Integrated Platform:

Professor Wu Gang emphasized that complex AF ablation (e.g., linear ablation for persistent AF, mitral isthmus ablation) requires high‑precision geometric reconstruction, real‑time contact status feedback, and precise energy delivery.

Synergy of Saline Irrigated and Contact Force Monitoring:

The catheter is available in three configurations: non‑irrigated, 6‑hole irrigated, and 66‑hole irrigated. The inclusion of irrigation in PFA is not redundant; combined with stable physical tissue contact, it promotes uniform transmural lesion formation in high‑impedance regions while significantly reducing the risks of blood pooling and hemolysis.

Quantitative Ablation Index and Efficient Continuous Discharge:

The system retains the familiar RF interface design and operating habits from the same platform, facilitating ease of use for physicians. The core incorporates a Pulsed Field Ablation Index, which shows minimal error in correlating with actual tissue lesion size, enabling continuous discharge without single‑shot count limitations and effectively overcoming the discharge‑count bottlenecks found in some similar systems. Standard energy of 1800V can be used for routine areas, while high‑energy mode is available for the most challenging mitral isthmus linear ablation. Energy dose and lesion prediction are quantified through the Pulsed Field Ablation Index, ensuring transmural lesions while significantly shortening procedure time.

Expert Discussion:

Professor Zang Xiaobiao from Fuwai Central China Cardiovascular Hospital affirmed the quantitative value of the PFA Index, noting that when adjusting voltage and polarity, clinical decisions can reference the Index. Professor Liu Zhijun from the Cardiovascular Hospital of Ningxia Medical University noted that this integrated dual‑energy platform has been applied in complex AF ablation, mitral isthmus ablation, and accessory pathway ablation. Under special anatomical conditions where traditional RF ablation struggles, the dual‑energy pulse platform offers a new strategic option.

In addition to the symposium, MicroPort EverPace's booth attracted significant attention. A water tank simulator was set up at the booth, allowing attending scholars to gain hands‑on experience with the functions of the domestically produced mapping and ablation platform:

Dual‑Energy Discharge Hands‑On Experience:

The booth highlighted the compatibility of the Columbus™ 3D EP Navigation System as a dual‑energy integrated platform. The full software interface was made available for physicians to practice with the PulseMagic™ TrueForce™ Pressure‑Monitoring PFA Catheter.

Intracardiac Echocardiography (ICE) Automatic Modeling Experience:

The water tank simulator demonstrated the automatic modeling algorithm of the EasyEcho™ ICE Catheter. Participants experienced the system's intelligent image processing capabilities firsthand. The high‑precision dynamic anatomical reconstruction quality and the efficient, integrated acoustic‑electrical workflow received recognition from on‑site experts.

Loop Mapping and Pulse Discharge Experience:

Attendees were able to manipulate the PulseMagic™ Spiral Magnetic‑Electrical Positioning PFA Catheter, observing its spatial three‑dimensional configuration on the 3D mapping system. The standard workflow for pulmonary vein isolation using this catheter was simulated, allowing physicians to understand the modeling and ablation process through the high‑fidelity water tank model.

Moving forward, MicroPort EverPace will actively expand its global presence, continue to drive product iteration and clinical application expansion, provide patients and physicians with more comprehensive products and professional services, and deliver a globally competitive integrated solution for interventional diagnosis and treatment in electrophysiology.